Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease

NDA FilingSL1009Positive

AI Analysis

Summary

Saol Therapeutics announced the resubmission of its New Drug Application for SL1009 (DCA) to treat Pyruvate Dehydrogenase Complex Deficiency, an ultra-rare genetic disorder.

Outcome Details

Resubmission of New Drug Application

Importance:6/10

Sentiment:

0.30

NDA resubmissionultra-rare diseaseFDAorphan indication

Read the original article

Published by Drugs.com New Drug Applications on July 7, 2026 8:07 PM

Read Original